Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
about
Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T).Recent advances in diabetic nephropathyMicroalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective.Candesartan for the treatment of hypertension and heart failure.Hypertension and microalbuminuria: the new detrimental duo.Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.Management strategies for patients with hypertension and diabetes: why combination therapy is critical.Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).A brief review of biomarkers for preventing and treating cardiovascular diseases.Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.Reduction of mean arterial pressure and proteinuria by the effect of ACEIs (Lisinopril) in Kurdish hypertensive patients in Hawler CityEfficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis.Arterial hypertension in diabetes mellitus: from theory to clinical practice.Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).The relationship of management modality in Saudi patients with type 2 diabetes to components of metabolic syndrome, γ glutamyl transferase and highly sensitive C-reactive protein.Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?Renin-angiotensin-aldosterone system blockade in diabetes: role of direct renin inhibitors.Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.Urinary biomarkers for the early diagnosis of retinopathy and nephropathy in type 1 diabetes mellitus: a "steady stream" of information using proteomics.Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. Commentary.Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.Stability of miR-126 in Urine and Its Potential as a Biomarker for Renal Endothelial Injury with Diabetic Nephropathy.High ambient glucose induces angiotensin-independent AT-1 receptor activation, leading to increases in proliferation and extracellular matrix accumulation in MES-13 mesangial cells.A community-based program to encourage patients' attention to their own diabetes care: pilot development and evaluation.Role of the renin angiotensin system in diabetic nephropathy.A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease.Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria.ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease.Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension.
P2860
Q34453476-ED1F00F1-546A-4786-9C60-F589A213B6DCQ34627724-882F071D-55A2-4324-BF4B-C426965B203CQ35520625-7F6C43B8-2C45-4B58-AEA8-7516A2A313DDQ35648485-12EC59C0-31D1-4157-B646-3CC71043BD66Q35814429-94EED5BA-44C4-4C7B-B58A-98CD8A96D402Q35974034-00D71B01-93CE-459C-93A2-1709D15B534BQ36289427-9907EBC3-B809-43D7-B968-936C4937AE4CQ36392677-9DFBD22C-0D47-45B5-8F6E-A3BAC7A2CC48Q36392987-7C6ED7A9-B1B2-4DF0-BDAA-01771D7A73BBQ36449894-CF5725FD-4486-47F1-9D49-10B01B8D9726Q36480076-371350DE-ACBE-4212-8711-E59592122BD1Q36648115-164EF57D-D31F-4AB7-8B4A-FEA2AC63E97DQ36764872-707EC3F2-6FDD-482B-A37D-5696C8DE312DQ36766087-6A311F0F-DBE6-4BF7-B60E-53D642503E74Q37087865-8C9D54FF-CB98-4DC5-A145-6A484260FC7EQ37196376-AE6410DB-F760-4CD9-BE8A-25BCFCF232C6Q37415058-89898342-3B15-4D63-A776-70828B4447DEQ37449207-C77CA98E-0E07-4AE6-A36D-00ABFE61ED80Q37505849-6D1DD6A0-B5DD-4783-B1A0-5FBB90ED2A22Q37553108-F086585E-3CBA-4062-89DE-2C86F2E4015BQ37634057-A11B8D05-EC2A-47C1-8A9E-7179AED5DFCCQ37702747-D4823F9F-3E84-477A-BDB9-DF99982B05A1Q37827620-CF72284A-12E7-4A2D-88BA-8FB52DEA04DBQ38275264-B73A149F-B85A-4165-B643-CC3371CA0A22Q39469574-79A97FFE-4DD3-48BD-9B5F-D9CFACCE8600Q39825133-EBB7D119-7CB2-4D5D-A8B0-AF4F1D40093DQ40383842-9D2CABA7-58D4-4DA7-9B3B-A9D6C5E51A8BQ42723231-C023D018-345B-49A0-A3F7-00D84797CEEEQ42946276-E39DFF82-FB66-4D53-B0BD-5FB67DBCE700Q43210222-568C39E2-3FC9-42F1-B2A3-5B790CAE0BD3Q45007901-D64EF02B-30BE-4E7E-9A1F-F3A198548D97Q45268057-4DF5DCB2-94FC-4BAF-BB05-BBC6AB40FB0CQ45701778-56BF071C-EC18-42FC-AB91-BCE4E8AFAD23Q46159940-5F24A780-2EEC-4810-B97C-0091E7B4EF7FQ46801144-EC8FBC32-8BE9-4E5E-8E7C-FB182F1A25A7
P2860
Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Renoprotective effects of addi ...... double-blind crossover trial.
@en
Renoprotective effects of addi ...... double-blind crossover trial.
@nl
type
label
Renoprotective effects of addi ...... double-blind crossover trial.
@en
Renoprotective effects of addi ...... double-blind crossover trial.
@nl
prefLabel
Renoprotective effects of addi ...... double-blind crossover trial.
@en
Renoprotective effects of addi ...... double-blind crossover trial.
@nl
P2093
P1433
P1476
Renoprotective effects of addi ...... double-blind crossover trial.
@en
P2093
Hans-Henrik Parving
Kasper Rossing
Lotte Pietraszek
Peter Jacobsen
P304
P356
10.2337/DIACARE.26.8.2268
P407
P577
2003-08-01T00:00:00Z